View Older Stories View More Recent Stories

Mar 29, 2018 08:02AM Citius Pharmaceuticals (CTXR) Announces $2 Million Registered Direct Offering Priced At-the-Market

Mar 29, 2018 08:00AM Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

Mar 6, 2018 08:00AM Citius Reports Progress in Hemorroid Treatment Program

Feb 15, 2018 08:08AM Citius Pharmaceuticals (CTXR) Reports Enrollment Of First Patient In The Mino-Lok Phase 3 Trial

Feb 15, 2018 08:00AM Citius Announces Enrollment Of First Patient In The Mino-Lok™ Phase 3 Trial

Feb 13, 2018 08:00AM Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias

Jan 31, 2018 08:00AM Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

Jan 4, 2018 08:00AM Citius Pharmaceuticals to Present at Biotech Showcase™ 2018

Dec 18, 2017 08:02AM Citius Pharmaceuticals (CTXR) Announces 1.28M Share Common Offering at $4.69/Sh

Dec 18, 2017 08:00AM Citius Announces $6 Million Registered Direct Offering Priced At-the-Market

Dec 4, 2017 01:36PM Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational

Oct 31, 2017 08:00AM Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational Trial

Oct 17, 2017 09:00AM Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference

Oct 11, 2017 09:04AM Citius Pharmaceuticals (CTXR) Discusses Recent developments, Financial Results in Shareholder Letter

Oct 11, 2017 09:00AM Citius Pharmaceuticals Issues Shareholder Letter

Sep 18, 2017 02:03PM Citius Pharmaceuticals (CTXR) Halted on LUDP

Sep 5, 2017 07:01AM Citius Pharmaceuticals (CTXR) Reports Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting

Sep 5, 2017 07:00AM Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting

Aug 10, 2017 11:30AM Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to Ring The Nasdaq Stock Market Opening Bell

Aug 8, 2017 11:25AM Citius Pharmaceuticals, Inc. Announces Closing of Public Offering

Aug 3, 2017 09:36AM Citius Pharmaceuticals (CTXR) Prices $6.8M Public Offering of Common Stock, Warrants

Aug 3, 2017 09:31AM Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market

Jun 13, 2017 10:37AM Citius Pharmaceuticals Presents At The 2017 Marcum MicroCap Conference

Jun 8, 2017 05:00PM Citius Pharmaceuticals Announces Reverse Stock Split

Jun 6, 2017 12:30PM Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

Mar 23, 2017 07:00AM Citius Pharma Announces Addition of South America to World License

Feb 10, 2017 07:00AM Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

Jan 11, 2017 07:00AM Citius' Mino-Lok™ Addresses Resistant Pathogens

Dec 21, 2016 07:00AM Citius Pharmaceuticals to Present at 9th Annual Biotech Showcase

Dec 8, 2016 07:00AM Citius Moves Forward with Mino-Lok™ Phase 3 Trial

Oct 20, 2016 07:00AM Citius Pharmaceuticals to Present at the Dawson James 2016 Small Cap Growth Stock Conference

Sep 19, 2016 07:00AM Citius Pharmaceuticals to Present at the 2016 Aegis Growth Conference

Sep 13, 2016 07:00AM Citius Initiates Mino-Lok™ Phase 3 Trial

Sep 8, 2016 07:00AM Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok™

Sep 8, 2016 07:00AM Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok™

Sep 7, 2016 10:32AM Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Sep 7, 2016 10:32AM Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Aug 23, 2016 07:00AM Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments

Aug 1, 2016 07:00AM Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements

Jul 25, 2016 07:00AM Citius Pharmaceuticals Addresses Problem That Affects 10 Million People in the U.S.: Hemorrhoids

Jul 18, 2016 07:00AM Citius Pharmaceuticals Completes Feasibility Study of Investigator Sites for Mino-Lok™ Phase 3 Trials

Jul 1, 2016 05:00PM Citius Pharmaceuticals Discontinues Suprenza™ To Focus on Core Assets

Jun 28, 2016 07:00AM Citius Pharmaceuticals, Inc. Announces Appointment of Dr. Eugene Holuka to Its Board of Directors

May 12, 2016 07:00AM Citius Announces Completion of Private Placement Financing

Apr 4, 2016 07:00AM Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences

Mar 23, 2016 07:00AM Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO

Mar 7, 2016 07:00AM Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences

Feb 1, 2016 07:00AM Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids

Oct 8, 2015 07:00AM Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors

Oct 6, 2015 07:00AM Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors

View More Recent Stories View Older Stories